Chidamide is a novel benzamide-type histone deacetylase (HDAC) inhibitor. People have investigated the effects of CS055 on proliferation, differentiation and apoptosis in human leukaemia cell lines and primary myeloid leukaemia cells.[1]

Histone deacetylases (HDACs) is a series of enzymes functioning to acetylate and deacetylate the amino-terminal lysine residues of histones, which result in the remodeling of the chromatin structures and affect the accessibility of the chromatin to transcription factors to start gene transcription.[2]

Chidamide has effect on cell cycle, it significantly reduced the S phase cell fraction, while inducing a marked increase in the G1 phase cell fraction in BEL-7402 and HCC-9204 cells with different p53 statuses. Chidamide signifiantly altered the number of cells in the phase fractions with an increase in dose.[2]

The results of the present study suggest that Chidamide is a HDACi with potential therapeutic value in several haematological malignancies via the inhibition of cell proliferation, inducing differentiation and apoptosis in human cells. Chidamide is a new HDACi with potential therapeutic values in several haematological malignancies via the inhibition of cell proliferation, inducing differentiation and apoptosis in human leukaemia cells.[1]

References:
[1] Gong K, Xie J, Yi H, Li W.  CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosisand differentiation in human leukaemia cells. Biochem J. 2012 May 1;443(3):735-46.
[2] Wang H1, Guo Y, Fu M, Liang X, etal.  , Antitumor activity of Chidamide in hepatocellular carcinoma cell lines. Mol Med Rep. 2012 Jun;5(6):1503-8.